

INVESTIGATOR'S CURRICULUM VITAE (synthesis)

Name

Academic Title	First Name	Family Name	Qualifications
MD, Professor Neurology	Alessandro	Stefani	Director Parkinson's CENTER, DEPT. SYSTEM MEDICINE UNIV TOR VERGATA ROME ITALY

- *Medical Doctor since 1984 (University of Rome La Sapienza);*
- *Medical Military Officer, 1986-1987;*
- *Certified Neurologist since 1988;*
- *Post-Doctoral Fellow, University of Tennessee, 1988-89;*
- *Assistant Professor, Università La Sapienza, since 1991;*
- *Researcher (tenure tract), University Tor vergata since 2001;*
- *Associate Professor, since 2002;*
- *Eligibility to Full Professorship since 2014*

- *In charge of Dementia Services, Policlinico Tor Vergata from 1999 to 2007/8*
- *Director of Parkinson's Centre, Fondazione Policlinico Tor Vergata, since 2009. Responsible experimental PDTA (hospital/metropolitan area 260,000 citizens) for prevention and monitoring of extrapyramidal syndromes*

Prof Stefani plays a leading role in different neuroscience fields. Amongst his specific fields is to remark the clinical and functional follow-up of Parkinsonian patients submitted to deep brain stimulation, the electrophysiological and pharmacological counterparts of animal's models of Parkinson (in vivo; in vitro; patch-clamp), the experience on CSF biomarkers of neurodegenerative CNS diseases, as well as his involvement in numerous trials (from stage II to stage IV)

Registered in the following societies: Society for Neuroscience (US); IBAGS; Limpe; Società Italiana di Neurologia.

He is author of about 200 papers internationally reviewed (PUBMED; NOT including abstracts or congress presentations)

H factor = 44

Teaching Responsibilities: among the others, In charge (coordinator) of Neurology & Psichiatria course at Odontoiatrc faculty for Vergata

Current position and discipline

Professor in Neurology , Dept System Medicine; in charge of Parkinson's disease unit (defined by Italian rules as "UOSD CENTRO PARKINSON, AZIENDA POLICLINICO TOR VERGATA")
Idoneity to Full Professorship chair since 2014

Medical licence / registration number and issue date (if applicable)

Medical licence n 35918 issued in 1985

Current employer

Institution	University of Rome Tor Vergata/Hospital Tor Vergata		
Department	Clinical Neuroscience, Dept System Medicine		
Address	Viale Oxford 81- 00133 Rome	Country: Italy	
Telephone	0039 06-20903119	Fax	0039 06-20903118
Email	stefani@uniroma2.it; alex.stefani@alice.it; stefani.alessandro@pec.it		

Medical career history (add further lines as required)

Dates from to	Position	Institution and department
1984	Medical Doctor	University of Rome La Sapienza
1988	Certified neurologist	University of Rome La Sapienza
1986-	Admitted to PH Program , XIV cycle	University of Rome, Tor Vergata

Education (add further lines as required)

All relevant major medical qualifications

Year	Qualification	Academic Institution where obtained
2001	Associate Professor	University of Rome Tor Vergata
2004	Visiting Professor	Northwestern University, Chicago
2014/2020	Entitled to Full Professor	MIUR

Experience in clinical trials

All major trials conducted over at least the last 5 years

<input checked="" type="checkbox"/> Yes, since:	1995	<input type="checkbox"/> No	Total number of trials worked on	➤ 20														
If yes, give details below: until 2009																		
<table> <tr> <td>1) Parkinson's Disease</td> <td>phase III -2002</td> </tr> <tr> <td>2) Safety, tolerability and efficacy of dopaminergic agonist in advanced Parkinson's Disease</td> <td>phase III -2004</td> </tr> <tr> <td>3) Motor complication in Parkinson's Disease</td> <td>phase III -2005</td> </tr> <tr> <td>4) Treatment of Parkinson's Disease</td> <td>phase III -2006</td> </tr> <tr> <td>5) Treatment of Parkinson's Disease</td> <td>phase III -2008</td> </tr> <tr> <td>6) Treatment in early Parkinson's Disease</td> <td>phase III -2009</td> </tr> <tr> <td>7) Executive function in Parkinson's Disease</td> <td>phase III -2009</td> </tr> </table>					1) Parkinson's Disease	phase III -2002	2) Safety, tolerability and efficacy of dopaminergic agonist in advanced Parkinson's Disease	phase III -2004	3) Motor complication in Parkinson's Disease	phase III -2005	4) Treatment of Parkinson's Disease	phase III -2006	5) Treatment of Parkinson's Disease	phase III -2008	6) Treatment in early Parkinson's Disease	phase III -2009	7) Executive function in Parkinson's Disease	phase III -2009
1) Parkinson's Disease	phase III -2002																	
2) Safety, tolerability and efficacy of dopaminergic agonist in advanced Parkinson's Disease	phase III -2004																	
3) Motor complication in Parkinson's Disease	phase III -2005																	
4) Treatment of Parkinson's Disease	phase III -2006																	
5) Treatment of Parkinson's Disease	phase III -2008																	
6) Treatment in early Parkinson's Disease	phase III -2009																	
7) Executive function in Parkinson's Disease	phase III -2009																	
Selection of recent trials																		
Year	Study phase	Very brief description	As principal investigator / sub-investigator / other support role															
2010	IV	Observational study focused on non-motor symptoms in PD patients	Sub-I															
2010	IV	Open label pharmacological trials in advanced PD patient	Sub-I															

2013	III	Observational study on PD patients undergoing second line treatment	PI
2017	II	Dr Reddy-EXN-32, PHase 2, closed	PI
2017	II	Sunovion CTH.201 (APL-130277), N = 3. Closed	PI
2014-2016	III	O Kyowa 6002-014 (Istradefylline)	PI
2017-8	IV	Zambon Synapses (safinamide), fase 4, N = 55	PI
2017-8	IV	Abbvie M15-535 (Duodopa)	PI
2018	II	Prexton PTX002331 (foliglurax), closed	PI
2020	IV	EON, Opicapone	PI
2020	II	Tavapadon	PI
2020	III	IPX-203	PI
2021	II	ORCHESTRA	PI
2021	li	Tavapadon (Tempo 02-Tempo 03/4	PI

I confirm that the information presented above is an accurate representation of my current status

Signature:

Print name:

Alessandro Stefani

Date: 2021

